Anti-Müllerian hormone predicts benefit of chemo + endocrine therapy in under-55s with breast cancer

Anti-Müllerian hormone (AMH) appears to foretell the payment of chemotherapy positive endocrine therapy (CET) versus ET unsocial successful premenopausal women younger than 55 years with hormone receptor-positive/human epidermal maturation origin receptor 2-negative bosom crab with a recurrence people (RS) ≤25, according to a survey published online July 24 successful the Annals of Oncology.